Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis
- PMID: 29357265
- DOI: 10.1164/rccm.201711-2202OC
Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis
Abstract
Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical predictors and outcomes of patients with frequently exacerbating disease are not well described.
Objectives: To establish if there is a "frequent exacerbator phenotype" in bronchiectasis and the impact of exacerbations on long-term clinical outcomes.
Methods: We studied patients with bronchiectasis enrolled from 10 clinical centers in Europe and Israel, with up to 5 years of follow-up. Patients were categorized by baseline exacerbation frequency (zero, one, two, or three or more per year). The repeatability of exacerbation status was assessed, as well as the independent impact of exacerbation history on hospitalizations, quality of life, and mortality.
Measurements and main results: A total of 2,572 patients were included. Frequent exacerbations were the strongest predictor of future exacerbation frequency, suggesting a consistent phenotype. The incident rate ratios for future exacerbations were 1.73 (95% confidence interval [CI], 1.47-2.02; P < 0.0001) for one exacerbation per year, 3.14 (95% CI, 2.70-3.66; P < 0.0001) for two exacerbations, and 5.97 (95% CI, 5.27-6.78; P < 0.0001) for patients with three or more exacerbations per year at baseline. Additional independent predictors of future exacerbation frequency were Haemophilus influenzae and Pseudomonas aeruginosa infection, FEV1, radiological severity of disease, and coexisting chronic obstructive pulmonary disease. Patients with frequently exacerbating disease had worse quality of life and were more likely to be hospitalized during follow-up. Mortality over up to 5 years of follow-up increased with increasing exacerbation frequency.
Conclusions: The frequent exacerbator phenotype in bronchiectasis is consistent over time and shows high disease severity, poor quality of life, and increased mortality during follow-up.
Keywords: antibiotics; bronchiectasis; exacerbations; infection; mortality.
Comment in
-
Bronchiectasis: Phenotyping an Orphan Disease.Am J Respir Crit Care Med. 2018 Jun 1;197(11):1371-1373. doi: 10.1164/rccm.201802-0211ED. Am J Respir Crit Care Med. 2018. PMID: 29412693 No abstract available.
Similar articles
-
Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity.Arch Bronconeumol (Engl Ed). 2019 Feb;55(2):81-87. doi: 10.1016/j.arbres.2018.07.002. Epub 2018 Aug 16. Arch Bronconeumol (Engl Ed). 2019. PMID: 30119935 English, Spanish.
-
Antimicrobial peptides, disease severity and exacerbations in bronchiectasis.Thorax. 2019 Sep;74(9):835-842. doi: 10.1136/thoraxjnl-2018-212895. Epub 2019 Jul 5. Thorax. 2019. PMID: 31278172
-
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.Eur Respir J. 2018 Jan 31;51(2):1701953. doi: 10.1183/13993003.01953-2017. Print 2018 Feb. Eur Respir J. 2018. PMID: 29386336
-
Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention.Ann Transl Med. 2023 Jan 15;11(1):25. doi: 10.21037/atm-22-3437. Epub 2022 Nov 16. Ann Transl Med. 2023. PMID: 36760239 Free PMC article. Review.
-
Bronchiectasis in COPD patients: more than a comorbidity?Int J Chron Obstruct Pulmon Dis. 2017 May 11;12:1401-1411. doi: 10.2147/COPD.S132961. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28546748 Free PMC article. Review.
Cited by
-
Epidemiology of bronchiectasis.Eur Respir Rev. 2024 Oct 9;33(174):240091. doi: 10.1183/16000617.0091-2024. Print 2024 Oct. Eur Respir Rev. 2024. PMID: 39384303 Free PMC article. Review.
-
Reproducibility of an airway tapering measurement in computed tomography with application to bronchiectasis.J Med Imaging (Bellingham). 2019 Jul;6(3):034003. doi: 10.1117/1.JMI.6.3.034003. Epub 2019 Sep 16. J Med Imaging (Bellingham). 2019. PMID: 31548977 Free PMC article.
-
Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis.BMC Pulm Med. 2019 Apr 25;19(1):82. doi: 10.1186/s12890-019-0844-4. BMC Pulm Med. 2019. PMID: 31023284 Free PMC article.
-
Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study.Eur Respir J. 2018 Jul 27;52(1):1800766. doi: 10.1183/13993003.00766-2018. Print 2018 Jul. Eur Respir J. 2018. PMID: 29880655 Free PMC article.
-
Impact of non-cystic fibrosis bronchiectasis on critically ill patients in Korea: a retrospective observational study.Sci Rep. 2021 Aug 3;11(1):15757. doi: 10.1038/s41598-021-95366-z. Sci Rep. 2021. PMID: 34345008 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical